Global Health Intrinsic Value
Global Health (MEDANTA) median intrinsic value is ₹708.74 from 10 valuation models (range ₹450–₹1796), vs current price ₹1499.40 — -52.7% downside (Trading Above Calculated Value), margin of safety -100.0%. Check MEDANTA market cap trends to track the company's total market size over time.
MEDANTA Valuation Methods Summary — DCF, Graham Number & P/E
Global Health intrinsic value across 10 models vs current price ₹1499.40 — upside/downside and value range per method. For current market price and key ratios, visit Global Health share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹449.82 | ₹359.86 - ₹539.78 | -70.0% | EPS: ₹21.44, Sector P/E: 12x |
| Book Value Method | asset | ₹737.78 | ₹664.00 - ₹811.56 | -50.8% | Book Value/Share: ₹737.78, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹708.74 | ₹637.87 - ₹779.61 | -52.7% | Revenue/Share: ₹885.93, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹1248.89 | ₹1124.00 - ₹1373.78 | -16.7% | EBITDA: ₹1124.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1796.02 | ₹1436.82 - ₹2155.22 | +19.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹449.82 | ₹404.84 - ₹494.80 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹449.82 | ₹404.84 - ₹494.80 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹1262.22 | ₹1136.00 - ₹1388.44 | -15.8% | ROE: 14.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹596.58 | ₹536.92 - ₹656.24 | -60.2% | EPS: ₹21.44, BVPS: ₹737.78 |
| Dividend Yield Method | dividend | ₹449.82 | ₹404.84 - ₹494.80 | -70.0% | DPS: ₹0.50, Target Yield: 3.5% |
MEDANTA Intrinsic Value vs Market Price — All Valuation Models
Global Health fair value range ₹450–₹1796 vs current market price ₹1499.40 across 10 valuation models. See Global Health P/B ratio trends to compare market price against book value per share.
MEDANTA Intrinsic Value Analysis — Undervalued or Overvalued?
Global Health median intrinsic value ₹708.74, current price ₹1499.40 — Trading Above Calculated Value by 52.7%, margin of safety -100.0%.
What is the intrinsic value of MEDANTA?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Global Health (MEDANTA) is ₹708.74 (median value). With the current market price of ₹1499.40, this represents a -52.7% variance from our estimated fair value.
The valuation range spans from ₹449.82 to ₹1796.02, indicating ₹449.82 - ₹1796.02.
Is MEDANTA undervalued or overvalued?
Based on our multi-method analysis, Global Health (MEDANTA) appears to be trading above calculated value by approximately 52.7%.
MEDANTA Financial Health — Key Ratios vs Industry Benchmarks
Global Health financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.29 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 14.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.81x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MEDANTA Cash Flow Quality — Operating & Free Cash Flow
Global Health operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹714 Cr | ₹170 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹624 Cr | ₹264 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹612 Cr | ₹392 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹645 Cr | ₹474 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹311 Cr | ₹101 Cr | Positive Free Cash Flow | 7/10 |